Shield Therapeutics
Weybridge
About Shield Therapeutics
Shield Therapeutics is an independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need. During 2011 Shield will be commencing global pivotal Phase III studies of its lead asset, ST10-021, for the treatment of iron deficiency anaemia associated with inflammatory bowel disease and subsequently chronic kidney disease. The Company is headquartered in Wollerau, Switzerland.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $39.9M
- Funding stage: IPO
- Last round: Post-IPO Equity (Sep 2025)
- Ticker: lse:STX
- Website: shieldtherapeutics.com
- Phone: +44 (0) 191 511 8500
Industries & Categories
Biotechnology, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/shield-therapeutics-160211 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.